Elite Pharmaceuticals Inc. has shored up its supply of phentermine active ingredient for the next year.


Elite Pharmaceuticals, phentermine, active pharmaceutical ingredient, API, pharmaceuticals, phentermine HCl tablets, phentermine HCl capsules, appetite suppressant














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Elite announces supply pact for phentermine API

December 13th, 2012

NORTHVALE, N.J. – Elite Pharmaceuticals Inc. has shored up its supply of phentermine active ingredient for the next year.

The company said Thursday that it has in place an agreement with the its sole supplier of the active pharmaceutical ingredient for its product lines that include phentermine HCl tablets (37.5 mg) and the upcoming phentermine HCl capsules (15 mg and 30 mg).

Elite noted that in mid-October it had disclosed a supply limitation for the active ingredient.

"The purchase orders now in place will allow the company to obtain adequate amounts of API, although at a substantially higher price than previously paid, to supply both the phentermine tablet product and the soon-to-be-launched phentermine capsule products," Elite stated. "Elite anticipates that some of the increase in API pricing could be offset with increased manufacturing efficiencies."

An appetite suppressant, phentermine is typically used along with diet and exercise to treat obesity in people with risk factors such as high blood pressure, high cholesterol or diabetes.

Advertisement